Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA.

Am J Gastroenterol. 2010 Jun;105(6):1437-43. doi: 10.1038/ajg.2009.758. Epub 2010 Mar 16.

PMID:
20234350
2.

Celecoxib for the prevention of colorectal adenomatous polyps.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators.

N Engl J Med. 2006 Aug 31;355(9):885-95.

3.

[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].

Sheng JQ, Li SR, Yang XY, Zhang YH, Su H, Yu DL, Yan W, Geng HG.

Zhonghua Yi Xue Za Zhi. 2006 Feb 28;86(8):526-9. Chinese.

PMID:
16681880
4.

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.

5.

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G.

N Engl J Med. 2000 Jun 29;342(26):1946-52.

6.

Celecoxib: new indication. Colorectal cancer: no preventive benefit.

[No authors listed]

Prescrire Int. 2006 Feb;15(81):13-5.

PMID:
16548099
7.

Celecoxib in a 12-year-old boy with familial adenomatous polyposis.

Pérez-Segura P, Bodas A, Sereno M, Martínez-Amores B, Olivera H, Díaz S, López-Asenjo JA, Puente J, Maluenda C, Díaz-Rubio E.

Int J Clin Pharmacol Ther. 2010 Mar;48(3):230-2.

PMID:
20197018
8.

Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.

van Heumen BW, Roelofs HM, Vink-Börger ME, Dekker E, Mathus-Vliegen EM, Dees J, Koornstra JJ, Langers AM, Nagtegaal ID, Kampman E, Peters WH, Nagengast FM.

Orphanet J Rare Dis. 2013 Aug 6;8:118. doi: 10.1186/1750-1172-8-118.

9.

A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.

Moberly JB, Xu J, Desjardins PJ, Daniels SE, Bandy DP, Lawson JE, Link AJ, Truitt KE.

Clin Ther. 2007 Mar;29(3):399-412.

PMID:
17577461
10.
11.

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.

Circulation. 2006 Sep 5;114(10):1028-35.

12.

Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study.

Cheung R, Krishnaswami S, Kowalski K.

Clin Ther. 2007;29 Suppl:2498-510. doi: 10.1016/j.clinthera.2007.12.008.

PMID:
18164917
14.

Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study.

Huang K, Gutierrez LP, Bülow S, Gallinger S, Castells A, Eagle CJ, Church JM.

Fam Cancer. 2011 Jun;10(2):303-8. doi: 10.1007/s10689-011-9423-4.

PMID:
21359561
15.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

16.

Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis.

Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, Kuwada SK, Neklason DW, Disario JA, Lyon E, Hughes JP, Chey WY, White RL.

Gastroenterology. 2004 Aug;127(2):444-51.

PMID:
15300576
17.

Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.

Nutr Cancer. 2008;60 Suppl 1:30-5. doi: 10.1080/01635580802401317.

PMID:
19003578
18.

Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.

Birbara C, Ruoff G, Sheldon E, Valenzuela C, Rodgers A, Petruschke RA, Chang DJ, Tershakovec AM.

Curr Med Res Opin. 2006 Jan;22(1):199-210.

PMID:
16393445
19.

Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.

Sieper J, Klopsch T, Richter M, Kapelle A, Rudwaleit M, Schwank S, Regourd E, May M.

Ann Rheum Dis. 2008 Mar;67(3):323-9. Epub 2007 Jul 6.

20.

Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.

Supplemental Content

Support Center